StockNews.AI
CRVO
StockNews.AI
42 days

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

1. CervoMed announces presentations at AAIC 2025 in Toronto. 2. New results from Phase 2b study on neflamapimod will be shared. 3. Neflamapimod targets synaptic dysfunction in dementia with Lewy bodies. 4. Posters will be accessible on the company's website after the session.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical study updates can drive investor interest and confidence, similar to other biotech firms post-conference.

How important is it?

Upcoming data presentations could lead to increased interest and stock price volatility.

Why Short Term?

The timing of the conference and study results will likely affect CRVO's price immediately.

Related Companies

BIIBADUSABBVSNYPFE
July 08, 2025 07:00 ET  | Source: CervoMed Inc. BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). Details of the AAIC Developing Topics presentations are as follow: Poster Title: Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co-PathologyFormat: In-person PosterSession Name: Developing Topics: Drug DevelopmentPoster Number: #108769Date and Time: Sunday, July 27, 2025 from 7:30 AM – 4:15 PM EDTPoster Title: Impact of AD Co-Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy BodiesFormat: Virtual PresentationSession Name: Developing Topics Poster Number: #108885 The posters will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation. About CervoMedCervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB. Investor Contact: PJ KelleherLifeSci AdvisorsInvestors@cervomed.com617-430-7579

Related News